Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
SHANGHAI, China, April 24, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, May 2nd, 2018 at 8:30am ET to discuss financial results for the full year ended December 31, 2017. On the call, Zai Lab’s senior management team will also provide the latest status update on the Company’s various development programs.
Investor Conference Call Details
Date: Wednesday, May 2nd, 2018
Time: 8:30am ET
Dial-In Details: 1-866-394-4355 (US); 1-314-888-4344 (International); 4006828609 (China)
Conference ID: 5836799
A live webcast and replay will be available on the Zai Lab investor website: http://ir.zailaboratory.com. Please note, on Monday, April 30th, 2018 Zai Lab intends to file its Form 20-F for the Year Ended December 31, 2017.
About Zai Lab
Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.
Contact:
Zai Lab
Billy Cho
+86 137 6151 2501
[email protected]
Solebury Trout
John Graziano
+1 646 378 2942
[email protected]
